EA035026B1 - Производные 2,3,4,5-тетрагидропиридин-6-амина - Google Patents
Производные 2,3,4,5-тетрагидропиридин-6-амина Download PDFInfo
- Publication number
- EA035026B1 EA035026B1 EA201890769A EA201890769A EA035026B1 EA 035026 B1 EA035026 B1 EA 035026B1 EA 201890769 A EA201890769 A EA 201890769A EA 201890769 A EA201890769 A EA 201890769A EA 035026 B1 EA035026 B1 EA 035026B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- dementia
- mmol
- added
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15186394 | 2015-09-23 | ||
| EP16172005 | 2016-05-30 | ||
| PCT/EP2016/072710 WO2017050978A1 (en) | 2015-09-23 | 2016-09-23 | 2,3,4,5-tetrahydropyridin-6-amine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201890769A1 EA201890769A1 (ru) | 2018-09-28 |
| EA035026B1 true EA035026B1 (ru) | 2020-04-20 |
Family
ID=56985626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890769A EA035026B1 (ru) | 2015-09-23 | 2016-09-23 | Производные 2,3,4,5-тетрагидропиридин-6-амина |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180334447A1 (enExample) |
| EP (1) | EP3353163B1 (enExample) |
| JP (1) | JP2018527387A (enExample) |
| KR (1) | KR20180053357A (enExample) |
| CN (1) | CN108026069A (enExample) |
| AU (1) | AU2016328589A1 (enExample) |
| BR (1) | BR112018005591A2 (enExample) |
| CA (1) | CA2995161A1 (enExample) |
| EA (1) | EA035026B1 (enExample) |
| HK (1) | HK1254800A1 (enExample) |
| IL (1) | IL258217A (enExample) |
| MX (1) | MX2018003565A (enExample) |
| TW (1) | TW201726651A (enExample) |
| WO (1) | WO2017050978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022511167A (ja) * | 2018-04-23 | 2022-01-31 | 塩野義製薬株式会社 | 選択的ｂａｃｅ１阻害活性を有する二環式複素環誘導体 |
| CN112313238B (zh) | 2018-04-27 | 2025-01-17 | 盐野义制药株式会社 | 具有选择性bace1抑制活性的四氢吡喃并噁嗪衍生物 |
| CN114380736B (zh) * | 2020-10-21 | 2023-10-03 | 复旦大学 | 一种2,3,4,5-四氢吡啶类化合物的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011009943A1 (en) * | 2009-07-24 | 2011-01-27 | Novartis Ag | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |
| WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| WO2015124576A1 (en) * | 2014-02-19 | 2015-08-27 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2518059A4 (en) * | 2009-12-24 | 2013-05-29 | Shionogi & Co | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE |
| US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| CA2799640C (en) * | 2010-06-09 | 2018-10-16 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
-
2016
- 2016-09-21 TW TW105130403A patent/TW201726651A/zh unknown
- 2016-09-23 CN CN201680055231.XA patent/CN108026069A/zh active Pending
- 2016-09-23 US US15/761,304 patent/US20180334447A1/en not_active Abandoned
- 2016-09-23 BR BR112018005591A patent/BR112018005591A2/pt not_active Application Discontinuation
- 2016-09-23 WO PCT/EP2016/072710 patent/WO2017050978A1/en not_active Ceased
- 2016-09-23 MX MX2018003565A patent/MX2018003565A/es unknown
- 2016-09-23 CA CA2995161A patent/CA2995161A1/en not_active Abandoned
- 2016-09-23 AU AU2016328589A patent/AU2016328589A1/en not_active Abandoned
- 2016-09-23 EA EA201890769A patent/EA035026B1/ru not_active IP Right Cessation
- 2016-09-23 EP EP16770283.6A patent/EP3353163B1/en active Active
- 2016-09-23 HK HK18113885.1A patent/HK1254800A1/zh unknown
- 2016-09-23 KR KR1020187010344A patent/KR20180053357A/ko not_active Withdrawn
- 2016-09-23 JP JP2018514794A patent/JP2018527387A/ja active Pending
-
2018
- 2018-03-19 IL IL258217A patent/IL258217A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011009943A1 (en) * | 2009-07-24 | 2011-01-27 | Novartis Ag | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |
| WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| WO2015124576A1 (en) * | 2014-02-19 | 2015-08-27 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018005591A2 (pt) | 2018-10-09 |
| IL258217A (en) | 2018-05-31 |
| CA2995161A1 (en) | 2017-03-30 |
| CN108026069A (zh) | 2018-05-11 |
| KR20180053357A (ko) | 2018-05-21 |
| JP2018527387A (ja) | 2018-09-20 |
| WO2017050978A1 (en) | 2017-03-30 |
| TW201726651A (zh) | 2017-08-01 |
| EA201890769A1 (ru) | 2018-09-28 |
| EP3353163A1 (en) | 2018-08-01 |
| AU2016328589A1 (en) | 2018-03-01 |
| HK1254800A1 (zh) | 2019-07-26 |
| MX2018003565A (es) | 2018-06-18 |
| EP3353163B1 (en) | 2020-02-05 |
| US20180334447A1 (en) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020215380A1 (en) | Heterocyclic compound and use thereof | |
| JP4018545B2 (ja) | Ｆｓａｄのためのｎｅｐ阻害剤としてのｎ−フェンプロピルシクロペンチル−置換グルタルアミド誘導体 | |
| KR101861942B1 (ko) | 신경 발생을 자극할 수 있는 n-페닐-락탐 유도체 및 이의 신경 장애 치료에서의 용도 | |
| JP2019521082A (ja) | Ｌｓｄ１／ｈｄａｃ二重阻害剤としてのシクロプロピル−アミド化合物 | |
| RS62133B1 (sr) | Tetrahidro-1h-pirido[3,4-b]indol antiestrogeni lekovi | |
| EA031041B1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
| EA024716B1 (ru) | Производные 5-(3-аминофенил)-5-алкил-5,6-дигидро-2h-[1,4]оксазин-3-амина | |
| US11345666B2 (en) | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT | |
| JP2024063191A (ja) | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 | |
| KR20240115978A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| US4443464A (en) | (+)-2-[1-(2,6-Dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene and the method for the treatment of human beings suffering from nervous disarrangements, in particular migraine | |
| JP2022512652A (ja) | Ｐ２ｘ３拮抗薬での皮膚掻痒症の治療 | |
| DE69517433T2 (de) | Benzozykloalkenverbindungen, deren herstellung und verwendung | |
| JP2024510778A (ja) | １，３－置換シクロブチル誘導体及びその使用 | |
| EA035026B1 (ru) | Производные 2,3,4,5-тетрагидропиридин-6-амина | |
| KR20230031321A (ko) | 치환된 페닐 또는 피리디닐 모이어티를 갖는 serd 트리시클릭 화합물의 제조 방법 | |
| US9463187B2 (en) | Methylphenidate derivatives and uses of them | |
| TW201821404A (zh) | 作為ROR γ調節劑之三環碸 | |
| JP7569953B2 (ja) | Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法並びに使用のための用量レジメン | |
| JP2010526133A (ja) | ３，４−ジヒドロキナゾリン誘導体 | |
| JP7282036B2 (ja) | 新規の芳香族化合物 | |
| JP3112356B2 (ja) | シクロペンテノン化合物及び該化合物を有効成分とする脳機能改善薬 | |
| BR122025005591B1 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit | |
| BR122025005591A2 (pt) | Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit | |
| HK1263406B (zh) | 作为双重lsd1/hdac抑制剂的环丙基-酰胺化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |